Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice
2 other identifiers
observational
1,788
1 country
1
Brief Summary
This study is conducted in Europe. The aim of this study is to investigate Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in daily Practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2015
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 30, 2014
CompletedFirst Posted
Study publicly available on registry
October 2, 2014
CompletedStudy Start
First participant enrolled
March 26, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 16, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
November 16, 2015
CompletedApril 17, 2018
April 1, 2018
8 months
September 30, 2014
April 16, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Frequency of patients achieving HbA1c reduction of at least 1%-point
Week 0, week 52
Secondary Outcomes (8)
Change in HbA1c (Glycosylated haemoglobin))
Week 0, week 104
Change in body weight
Week 0, week 104
Frequency of patients achieving HbA1c reduction of at least 1%-point
After 4 and 24 months of treatment
Frequency of patients achieving HbA1c target (<=7%)
After 4, 12 and 24 months
Frequency of patients achieving a body weight reduction of at least 3%
After 4, 12 and 24 months
- +3 more secondary outcomes
Study Arms (1)
A
Interventions
Eligibility Criteria
All consecutive subjects initiating liraglutide in 2011 according to Victoza® SmPC meeting the inclusion criteria will be enrolled.
You may qualify if:
- Subjects of age above 18 years as per Victoza® SmPC par.4.2 and 5.1 diagnosed with type 2 diabetes receiving the first prescription of liraglutide in 2011
You may not qualify if:
- None. Available data from all eligible patients for each center, will be included
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Novo Nordisk A/Slead
Study Sites (1)
Novo Nordisk Investigational Site
Rome, 00144, Italy
Related Publications (1)
Lapolla A, Berra C, Boemi M, Bossi AC, Candido R, Di Cianni G, Frontoni S, Genovese S, Ponzani P, Provenzano V, Russo GT, Sciangula L, Simioni N, Bette C, Nicolucci A; NN2211-4118 Study Group. Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study. Adv Ther. 2018 Feb;35(2):243-253. doi: 10.1007/s12325-017-0652-2. Epub 2017 Dec 21.
PMID: 29270781RESULT
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Global Clinical Registry (GCR, 1452)
Novo Nordisk A/S
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 30, 2014
First Posted
October 2, 2014
Study Start
March 26, 2015
Primary Completion
November 16, 2015
Study Completion
November 16, 2015
Last Updated
April 17, 2018
Record last verified: 2018-04